期刊文献+

第二次单倍体造血干细胞移植治疗首次移植失败再生障碍性贫血并发淋巴瘤1例 被引量:3

Second haploidentical hematopoietic stem cell transplantation for aplastic anemia complicated by lymphoma in one case undergoing a failed first transplantation
下载PDF
导出
摘要 背景:急性重型再生障碍性贫血第一次异基因造血干细胞移植失败对患儿是严重致命的,若同时合并有继发性淋巴瘤等多种并发症,治疗就更为棘手,目前无成功方法可借鉴。目的:探讨第二次HLA单倍体造血干细胞移植治疗首次移植失败且并发淋巴瘤的急性重型再生障碍性贫血患儿的有效性和安全性。方法:回顾性分析1例急性重型再障患儿的二次造血干细胞移植的临床资料:患儿男,3岁,2011年11月25日行第一次非血缘异基因外周血干细胞移植(供受者HLA为8/10相合,血型主要不合),移植后粒细胞和血小板造血分别在11 d和14 d恢复,移植后30 d DNA移植植入鉴定和染色体检测均示移植成功植入,术后35 d出现皮肤Ⅰ度移植物抗宿主病,激素治疗后消失,术后54 d因出现自身免疫性溶血性贫血及纯红细胞再生障碍性贫血,给予大剂量丙种球蛋白冲击、激素及促红素等治疗好转,激素逐渐减量,EBV拷贝数逐渐升高,术后3个月患者出现发热、双侧颈部可触及数个肿大淋巴结,行B超引导下右侧颈部淋巴结穿刺活检,考虑移植后淋巴增殖性疾病,病理示:弥漫大B细胞淋巴瘤,治疗上减停免疫抑制剂,应用美罗华及CHOP方案化疗,淋巴结缩小,且EBV拷贝数下降,体温正常。移植术后5个月复查血象和骨髓象提示继发性植入失败,进而于2012年5月15日行第二次单倍体相合造血干细胞移植。供者为患儿的父亲,预处理方案为清髓性预处理方案:氟达拉滨+环磷酰胺+马利兰+米托蒽醌+抗CD52单克隆抗体。回输骨髓造血干细胞的同时输注脐带间充质干细胞。移植物抗宿主病预防:环孢素A+短程的甲氨喋呤+CD25单克隆抗体联合霉酚酸酯。回输的有核细胞分别为13.52×108/kg,CD34+细胞数为2.45×106/kg,无关供者脐带来源间充质干细胞的量为1×106/kg。随访时间为移植后24个月。结果与结论:移植后中性粒细胞达到0.5×109 L-1,血� BACKGROUND: It is fatal for children with acute severe aplastic anemia undergoing failed first allogeneic. If there are secondary lymphoma and other complications, treatment is more difficult. Up to now, there is yet no feasible treatment.OBJECTIVE: To investigate the possibility and safety of second haploidentical hematopoietic stem cell transplantation because of the failure in the first unrelated blood transplantation and secondary lymphoma. METHODS: A 3-year-old boy with severe aplastic anemia underwent HLA 8/10 matched unrelated peripheral blood stem cell transplantation on November 25, 2011. There was a major ABO mismatch. The time of neutrophil exceeding 0.5×109/L and platelets recovery exceeding 20×109/L were 11 and 14 days, respectively after transplantation. Bone marrow aspiration showed normal while full donor engraftment was found by chromosomal analyses on day 30. Grade I graft-versus-host disease occurred after 35 days. Autoimmune hemolytic anemia and pure red cell aplasia were also diagnosed on day +54. He was given high-dose gamma globulin, erythropoietin and glucocorticoids, and autoimmune hemolytic anemia and pure red cell aplasia were controlled. Unfortunately, on day +90, the boy suffered from fever and superficial lymph nodes of the bilateral neck. B ultrasound-guided needle biopsy was done on the right cervical lymph nodes, and post transplant lymphoproliferative disorder was considered. Pathological examination showed diffuse large B-cell lymphoma. Managements for patients consisted of withdrawal of immunosuppressive treatment and application of rituximab plus chemotherapy. After treatment, the lymph node shrank, Epstein-Barr virus copy number was decreased, and the body temperature recovered. However, on day +150, blood routine examination and bone marrow aspiration showed transplant failure. Then, the boy received the second haploidentical stem cell transplantation on May 15, 2012. The donor was his father. A myloablative condition regimen was selected: high-dose fludarabi
出处 《中国组织工程研究》 CAS CSCD 2014年第32期5244-5248,共5页 Chinese Journal of Tissue Engineering Research
关键词 造血干细胞移植 脐带 间质干细胞移植 贫血 再生障碍性 干细胞 移植 造血干细胞 脐带间充质干细胞 再生障碍性贫血 单倍体相合移植 非血缘 hematopoietic stem cell transplantation umbilical cord mesenchymal stem cell transplantation anemia, aplastic
  • 相关文献

参考文献17

  • 1Kedmi M, Resnick IB, Dray L,et al.A retrospective review of the outcome after second or subsequent allogeneic transplantation.Biol Blood Marrow Transplant.2009;15(4): 483-489. 被引量:1
  • 2Lawler M, McCann SR, Marsh JC,et al.Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA.Br J Haematol.2009;144(6):933-945. 被引量:1
  • 3Lacerda JF, Martins C, Carmo JA,et al.Haploidentical stem cell transplantation with purified CD34+ cells after a chemotherapy-alone conditioning regimen in heavily transfused severe aplastic anemia.Biol Blood Marrow Transplant.2005;11(5):399-400. 被引量:1
  • 4Passweg JR, Pérez WS, Eapen M,et al.Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia.Bone Marrow Transplant.2006;37(7): 641-649. 被引量:1
  • 5Bacigalupo A1, Oneto R, Bruno B,et al.Current results of bone marrow transplantation in patients with acquired severe aplastic anemia.Report of the European Group for Blood and Marrow transplantation.On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation.Acta Haematol.2000;103(1):19-25. 被引量:1
  • 6Chewning JH, Castro-Malaspina H, Jakubowski A,et al.Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure.Biol Blood Marrow Transplant.2007;13(11):1313-1323. 被引量:1
  • 7Korthof ET, Békássy AN, Hussein AA.Management of acquired aplastic anemia in children.Bone Marrow Transplant.2013;48(2):191-195. 被引量:1
  • 8Curtis RE, Travis LB, Rowlings PA,et al.Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.Blood.1999;94(7): 2208-2216. 被引量:1
  • 9González-Barca E, Domingo-Domenech E, Capote FJ,et al.Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.Haematologica.2007;92(11): 1489-1494. 被引量:1
  • 10Ciceri F, Lupo-Stanghellini MT, Korthof ET.Haploidentical transplantation in patients with acquired aplastic anemia.Bone Marrow Transplant.2013;48(2):183-185. 被引量:1

同被引文献27

  • 1Sica S, Metafuni E, Bellesi S, etal. Epstein-barr virus related lymphoproliferations after stem cell transplantation [ J ]. Mediterr J Hematol Infect Dis, 2009, 1(2): e2009019. 被引量:1
  • 2Nelson BP, Nalesnik MA, Babler DW, et al. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? [J]. Am J Surg Pathol, 2000, 24(3): 375- 385. 被引量:1
  • 3Giulino LB, Bussel JB, Neufeld EJ. Treatment with rituximab in benign and malignant hematologic disorders in children[J]. J Pediatr, 2007, 150(4): 338-344. 被引量:1
  • 4Swerdlow SH, Webher SA, Chandburn A, et al. Posttransplant lymphoproliferative disorders// Swerdlow SH, Campo E, Harris NL, et al. WHO classification of turnouts of haematopoietic and lymphoid tissues. 4th ed [ M]. Iyon: International Agency for Research on Cancer, 2008.. 342-349. 被引量:1
  • 5Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody ( rituximab ) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children[J]. Br J Hematol, 2001, 115 (1) : 112-118. 被引量:1
  • 6Cutis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after hone marrow transplantation: a multi-institutional study[J]. Blood, 1999, 94(7) : 2208-2216. 被引量:1
  • 7Worth A, Conyers R, Cohen J, et al. Pre-emptive rituximab based on viraemia and T cell reconstitution~ a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation [J]. Br J Hematol, 2011, 155(3): 377-385. 被引量:1
  • 8Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV- specific T cells for biopsy-proven EBV+ lymphomas after allogeneie hematopoietie cell transplantation[J]. Blood, 2012, 119(11): 2644-2656. 被引量:1
  • 9Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein- Barr-virus-positive post-transplantation Iymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells [J]. Lancet, 2002, 360(9331): 436-442. 被引量:1
  • 10van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV lymphoproliferative disease following T-cell-depleted SCT [J]. Blood, 2001, 98(4), 972-978. 被引量:1

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部